Reporter brief
RCT evaluates urolithin A and fisetin on sleep quality and aging biomarkers in middle-aged and older adults
What happened
This randomized controlled trial compared four groups—placebo, 500 mg urolithin A, 500 mg fisetin, and a 300 mg urolithin A + 200 mg fisetin combination—over 12 weeks in middle-aged and older adults. Participants took daily capsules and underwent assessments at baseline, week 4, and week 12, including sleep quality measures (PSQI, actigraphy, polysomnography), aging biomarkers (DNA methylation, inflammatory cytokines), and gut microbiome analysis. The abstract describes the study design and planned assessments but does not report any results or findings.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Middle-aged and older adults
- Design
- Rct
- Sample
- —
- Journal
- Huazhong University of Science and Technology
- Published
- Aug 10, 2026
Effect size
Not recorded.
Caveats
- Assessment: Pending.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Sleep timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.